22 January 2021 - Lupkynis is the first FDA approved oral therapy for lupus nephritis, a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death.

Aurinia Pharmaceuticals today announced that the U.S. FDA has approved Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis. 

Lupkynis is now available to patients in the United States.

Read Aurinia Pharmaceuticals press release